Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omalizumab biosimilar - Kashiv BioSciences

Next Previous
Drug Profile

Omalizumab biosimilar - Kashiv BioSciences

Alternative Names: ADL-018; AVT-23

Latest Information Update: 26 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adello Biologics
  • Developer Kashiv BioSciences
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Asthma

Highest Development Phases

  • Preregistration Asthma; Chronic urticaria; Rhinosinusitis

Most Recent Events

  • 12 Sep 2025 Kashiv BioSciences and Cristalia enters into licensing and supply agreement for omalizumab biosimilar (ADL-018) in Latin America.
  • 28 Aug 2025 No recent reports of development identified for phase-I development in Asthma(In volunteers) in India (SC, Injection)
  • 05 Aug 2025 MS Pharma in-licenses omalizumab biosimilar from Kashiv Biosciences in middle east and north africa

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top